专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明申请

US20160195544A1 METHOD OF DIAGNOSING SEPSIS OR SEPSIS RISK 审中-公开
标题翻译：诊断肛门或食道风险的方法
公开(公告)号：US20160195544A1
公开(公告)日：2016-07-07
申请号：US14910962
申请日：2014-08-06
申请人： Minsoo KIM
发明人： Minsoo KIM
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , C07K14/705 , C07K14/7055 , G01N2333/7055 , G01N2800/24 , G01N2800/52
摘要： The present invention relates to methods of diagnosing sepsis or sepsis risk in a subject and methods of treating a patient for sepsis. The methods include detecting the presence of a subpopulation of neutrophils having an elevated integrin VLA-3 (CD49c/CD29) expression level in the subject. The method also includes contacting a biological sample from a subject with a reagent that binds specifically to integrin VLA-3 (CD49c/CD29) in the biological sample, detecting the reagent bound to integrin VLA-3, and determining the expression level of integrin VLA-3 in the sample. The invention further relates to a method of discriminating between sepsis and systemic inflammatory response syndrome (SIRS) and a method of treating a patient for SIRS which includes detecting the presence or absence of a subpopulation of neutrophils having an elevated integrin VLA-3 expression level in a subject having systemic inflammation.
摘要翻译：本发明涉及诊断受试者败血症或败血症风险的方法以及治疗患者败血症的方法。所述方法包括检测受试者中具有升高的整联蛋白VLA-3（CD49c / CD29）表达水平的嗜中性粒细胞亚群的存在。该方法还包括使来自受试者的生物样品与生物样品中与整联蛋白VLA-3（CD49c / CD29）特异性结合的试剂接触，检测与整联蛋白VLA-3结合的试剂，并测定整联蛋白VLA的表达水平 -3在样品中。本发明还涉及鉴别败血症和全身性炎症反应综合征（SIRS）的方法以及治疗患者SIRS的方法，该方法包括检测在具有升高的整联蛋白VLA-3表达水平的嗜中性粒细胞亚群中的存在或不存在具有全身炎症的受试者。

82. 发明申请

US20160166654A1 COLLAGEN-TARGETED NANOPARTICLES 审中-公开
公开(公告)号：US20160166654A1
公开(公告)日：2016-06-16
申请号：US14884646
申请日：2015-10-15
申请人： PURDUE RESEARCH FOUNDATION
发明人： John E. Paderi , Alyssa Panitch
IPC分类号： A61K38/39 , A61K38/10 , A61K38/08
CPC分类号： A61K38/39 , A61K9/146 , A61K38/08 , A61K38/10 , A61K47/62 , A61K47/6923 , A61K47/6929 , A61K47/6937 , A61K49/0002 , A61K49/0056 , A61K49/0065 , A61K49/0428 , B82Y5/00 , C07K14/7055
摘要： This invention relates to compositions comprising collagen binding peptides coupled to nanoparticles. The invention also relates to a method of imaging a collagenous matrix using a composition comprising collagen binding peptides coupled to nanoparticles.

83. 发明授权

US09173919B2 Collagen-targeted nanoparticles 有权
标题翻译：胶原靶向纳米粒子
公开(公告)号：US09173919B2
公开(公告)日：2015-11-03
申请号：US14000036
申请日：2012-02-16
申请人： John E. Paderi , Alyssa Panitch
发明人： John E. Paderi , Alyssa Panitch
IPC分类号： A61K38/10 , A61K47/48 , A61K49/00 , A61K49/04 , B82Y5/00 , C07K14/705 , A61K9/14
CPC分类号： A61K38/39 , A61K9/146 , A61K38/08 , A61K38/10 , A61K47/48238 , A61K47/48861 , A61K47/48884 , A61K47/48915 , A61K47/62 , A61K47/6923 , A61K47/6929 , A61K47/6937 , A61K49/0002 , A61K49/0056 , A61K49/0065 , A61K49/0428 , B82Y5/00 , C07K14/7055
摘要： This invention relates to compositions comprising collagen binding peptides coupled to nanoparticles. The invention also relates to a method of imaging a collagenous matrix using a composition comprising collagen binding peptides coupled to nanoparticles.
摘要翻译：本发明涉及包含与纳米颗粒偶联的胶原结合肽的组合物。本发明还涉及使用包含与纳米颗粒结合的胶原结合肽的组合物对胶原基质成像的方法。

84. 发明申请

US20150086557A1 NOVEL INTEGRIN alpha9 beta1 LIGAND AND USES THEREOF 审中-公开
标题翻译： NOVEL INTEGRIN alpha9 beta1 Ligand及其用途
公开(公告)号：US20150086557A1
公开(公告)日：2015-03-26
申请号：US14384206
申请日：2013-03-14
申请人： OSAKA UNIVERSITY
发明人： Kiyotoshi Sekiguchi , Ryoko Sato , Sachiko Ezoe
IPC分类号： C07K7/06 , C12N5/071 , G01N33/50 , C07K16/18 , C07K7/08
CPC分类号： C07K7/06 , A61K38/00 , C07K7/08 , C07K14/4702 , C07K14/7055 , C07K16/18 , C07K16/28 , C07K16/2839 , C07K2317/34 , C12N5/0602 , G01N33/502 , G01N2500/02 , G01N2500/04
摘要： Provided is a novel ligand for integrin α9β1 consisting of a peptide having the following amino acid sequence: (A) EDDMMEVPY (SEQ ID NO: 1) or (B) an amino acid sequence the same as the amino acid sequence represented by SEQ ID NO: 1 except for having deletion, substitution or addition of 1 to 3 amino acids. The novel ligand for integrin α9β1 has a higher binding affinity than those of tenascin-C and osteodontin, which are known ligands for integrin α9β1.
摘要翻译：提供一种由具有以下氨基酸序列的肽组成的整合素α9和bgr的新型配体：（A）EDDMMEVPY（SEQ ID NO：1）或（B）与SEQ ID NO：1所示的氨基酸序列相同的氨基酸序列 ID NO：1，除了缺失，取代或添加1至3个氨基酸。整合素α9和bgr1的新型配体具有比蜕皮素C和骨质疏松的更高的结合亲和力，其是用于整合素α9和bgr的已知配体1。

85. 发明申请

US20130323311A1 COLLAGEN-TARGETED NANOPARTICLES 有权
标题翻译：胶原靶向纳米颗粒
公开(公告)号：US20130323311A1
公开(公告)日：2013-12-05
申请号：US14000036
申请日：2012-02-16
申请人： John E. Paderi , Alyssa Panitch
发明人： John E. Paderi , Alyssa Panitch
IPC分类号： A61K38/10 , A61K9/14
CPC分类号： A61K38/39 , A61K9/146 , A61K38/08 , A61K38/10 , A61K47/48238 , A61K47/48861 , A61K47/48884 , A61K47/48915 , A61K47/62 , A61K47/6923 , A61K47/6929 , A61K47/6937 , A61K49/0002 , A61K49/0056 , A61K49/0065 , A61K49/0428 , B82Y5/00 , C07K14/7055
摘要： This invention relates to compositions comprising collagen binding peptides coupled to nanoparticles. The invention also relates to a method of imaging a collagenous matrix using a composition comprising collagen binding peptides coupled to nanoparticles.
摘要翻译：本发明涉及包含与纳米颗粒偶联的胶原结合肽的组合物。本发明还涉及使用包含与纳米颗粒结合的胶原结合肽的组合物对胶原基质成像的方法。

86. 发明申请

US20120114708A1 INTEGRIN HETERODIMER AND AN ALPHA SUBUNIT THEREOF 审中-公开
标题翻译：集成式高频交换器及其ALPHA子模块
公开(公告)号：US20120114708A1
公开(公告)日：2012-05-10
申请号：US13311757
申请日：2011-12-06
申请人： Donald GULLBERG
发明人： Donald GULLBERG
IPC分类号： A61K39/395 , G01N33/567 , A61P19/08 , A61K9/00 , A61P19/04 , C12N5/071 , C12N5/077
CPC分类号： C07K16/2839 , C07K14/70546 , C07K14/7055
摘要： A recombinant or isolated integrin heterodimer comprising a novel subunit α11 in association with a subunit β is described. The integrin or the subunit α11 can be used as marker or target of all types of cells. The integrin or subunit α11 thereof can be used as marker or target in different physiological or therapeutic methods. They can also be used as active ingredients in pharmaceutical compositions and vaccines.
摘要翻译：重组或分离的整联蛋白异二聚体，其包含与亚单位bgr结合的新亚基α11; 被描述。整合素或亚单位α11可用作所有类型细胞的标记物或靶标。整合素或其亚基α11可以用作不同生理或治疗方法的标记物或靶标。它们也可以用作药物组合物和疫苗中的活性成分。

87. 发明申请

US20110189095A1 CRKL TARGETING PEPTIDES 审中-公开
标题翻译： CRKL定位肽
公开(公告)号：US20110189095A1
公开(公告)日：2011-08-04
申请号：US13000231
申请日：2009-06-19
申请人： Wadih Arap , Paul J. Miniz , Renata Pasqualini
发明人： Wadih Arap , Paul J. Miniz , Renata Pasqualini
IPC分类号： A61K38/02 , C07K2/00 , C07K7/08 , C07K14/47 , C07K7/06 , C07K19/00 , C07K16/00 , C07K14/555 , C07K14/54 , C12N9/96 , C07K14/545 , C07K14/55 , C07K14/57 , C07K14/565 , C07K14/56 , C07K14/525 , C07K14/535 , C12N7/00 , C12N5/071 , C12N1/20 , C12N1/16 , C07K1/04 , C12N5/07 , C12Q1/02 , A61P35/00 , A61P35/02 , A61K49/00
CPC分类号： C07K14/7055 , A61K47/62 , C07K2319/01
摘要： Provided are methods and compositions for selectively targeting CRKL through the use of targeting peptides. Selective targeting of secreted CRKL through the use of a targeting peptide may be used, for example, in the treatment of cancer to deliver a chemotherapeutic compound, fusion protein, or fusion construct to a cancer cell or tissue.
摘要翻译：提供了通过使用靶向肽选择性靶向CRKL的方法和组合物。可以使用通过使用靶向肽来选择性靶向分泌的CRKL，例如用于治疗癌症以将化学治疗化合物，融合蛋白或融合构建体递送至癌细胞或组织。

88. 发明授权

US07807794B2 Anti-α2 integrin antibodies and their uses 有权
标题翻译：抗α2整合素抗体及其用途
公开(公告)号：US07807794B2
公开(公告)日：2010-10-05
申请号：US11601595
申请日：2006-11-17
申请人： Elias Lazarides , Catherine Mary Woods , Mark Bernard
发明人： Elias Lazarides , Catherine Mary Woods , Mark Bernard
IPC分类号： C07K16/28 , C07K16/46
CPC分类号： C07K16/2842 , A61K39/3955 , A61K47/6849 , A61K2039/505 , C07K14/7055 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/567 , C07K2317/76 , C07K2317/92 , C07K2319/00 , G01N33/6872 , G01N33/6893 , G01N2333/7055
摘要： The invention relates to anti-α2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of α2 integrin and inhibit the interaction of α2β1 integrin with collagen. Also disclosed are therapeutic uses of anti-α2 integrin antibodies in treating α2β1-mediated disorders, including anti-α2 integrin antibodies that bind to α2 integrin without activating platelets.
摘要翻译：本发明涉及抗α2整联蛋白抗体及其用途。公开了与α2整联蛋白的I结构域结合并抑制α2和bgr1整联蛋白与胶原蛋白相互作用的人源化抗体。还公开了抗α2整联蛋白抗体治疗α2和bgr1介导的病症的治疗用途，包括结合α2整联蛋白而不激活血小板的抗α2整联蛋白抗体。

89. 发明申请

US20080153756A1 Novel Peptides and Methods for the Treatment of Inflammatory Disorders 审中-公开
标题翻译：新型肽和治疗炎性疾病的方法
公开(公告)号：US20080153756A1
公开(公告)日：2008-06-26
申请号：US11874356
申请日：2007-10-18
申请人： Geoffrey Wayne Krissansen , Rupinder Kaur Kanwar , Katherine Woods
发明人： Geoffrey Wayne Krissansen , Rupinder Kaur Kanwar , Katherine Woods
IPC分类号： A61K38/04 , C07K7/00 , C07K14/00 , A61K48/00 , G01N33/53 , C07K16/18 , A61P29/00 , C07H21/00 , C12N15/63
CPC分类号： C07K14/7055 , A61K38/00 , C07K2319/30
摘要： Novel peptides, nucleic acids encoding them, and derivatives of the peptides are described. The peptides and nucleic acids are of use in modulating α4 integrin function and in treating α4 integrin-mediated inflammatory disorders.
摘要翻译：描述了新型肽，编码它们的核酸和肽的衍生物。肽和核酸可用于调节α4整联蛋白功能和治疗α4整联蛋白介导的炎症性疾病。

90. 发明申请

US20050113305A1 Compounds and methods for modulating cell-adhesion mediated drug resistance 有权
标题翻译：用于调节细胞粘附介导的耐药性的化合物和方法
公开(公告)号：US20050113305A1
公开(公告)日：2005-05-26
申请号：US10978202
申请日：2004-10-29
申请人： William Dalton , Jason Damiano , Anne Cress
发明人： William Dalton , Jason Damiano , Anne Cress
IPC分类号： A61K38/08 , C07K14/47 , C07K14/705
CPC分类号： A61K38/08 , C07K14/4747 , C07K14/7055 , A61K2300/00
摘要： Peptides and methods of their use for inhibiting drug and radiation-therapy resistance in cancerous cells in which efficacy of chemotherapy and/or radiotherapy of a patient is enhanced by administration of an effective amount of a peptide that inhibits cell adhesion mediated drug resistance (CAM-DR). Preferably, the peptide comprises D-amino acids having the sequence: kmviywkag (RZ-3)or is a variant or modified version thereof. The peptide is preferably administered to the patient prior to chemotherapy and/or radiation therapy. Inhibition of cell adhesion mediated drug resistance (CAM-DR) by RZ-3 in multiple myeloma cells is disclosed.
摘要翻译：肽及其用于抑制癌细胞中的药物和放射治疗抗性的方法，其中通过施用有效量的抑制细胞粘附介导的药物抗性的肽（CAM-1）来增强患者的化学疗法和/或放射疗法的功效， DR）。优选地，肽包含具有以下序列的D-氨基酸：<？in-line-formula description =“In-line Formulas”end =“lead”？> kmviywkag（RZ-3）<？in-line-formula description = “内联公式”end =“tail”？>或是其变体或修改版本。肽在化疗和/或放射治疗之前优选施用于患者。公开了通过RZ-3在多发性骨髓瘤细胞中抑制细胞粘附介导的药物抗性（CAM-DR）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式